Are the new EU GMP drafts changing how you manage documentation, computerised systems and AI?
About this Webinar
The European Medicines Agency draft updates to EU GMP introduce significant changes to Chapter 4 on documentation, a full revision of Annex 11 on computerised systems, and a new Annex 22 dedicated to Artificial Intelligence. These proposals signal a clear shift towards a more digital, data centric and tightly controlled GMP environment.
In this expert led Q&A session, Rephine specialists with extensive experience in GxP, computerised systems and inspections provide practical insight into what these draft changes mean in practice. The discussion focuses on regulatory intent, likely inspection expectations, and how pharmaceutical and life sciences organisations can prepare without overcomplicating their quality systems.
The session draws on real audit and inspection experience to clarify common questions around data integrity, cybersecurity, audit trails, cloud services and the acceptable use of AI within GMP processes.
The session will cover the following topics:
- Key changes to EU GMP Chapter 4 and the expanded definition of documentation formats
- What the revised Annex 11 means for computerised systems, audit trails and cybersecurity
- Regulatory expectations for suppliers, cloud services and data location
- The scope and limitations of Annex 22 and how Artificial Intelligence can be used responsibly in GMP
- Practical inspection expectations and common areas of regulatory focus
Watch the full webinar to understand how these EU GMP drafts may affect your organisation and how to prepare with confidence.
Agenda
00:02
Introduction and session overview
Introduction and session overview
09:10
EU GMP draft updates overview
Chapter 4, Annex 11 and the new Annex 22
EU GMP draft updates overview
Chapter 4, Annex 11 and the new Annex 22
12:05
Documentation, data integrity and hybrid systems
Documentation, data integrity and hybrid systems
14:41
Computerised systems, audit trails and
Computerised systems, audit trails and
cybersecurity expectations
20:34
Artificial Intelligence in GMP and Annex 22 explained
Artificial Intelligence in GMP and Annex 22 explained
24:48
Q&A
Inspection expectations, AI validation, suppliers and
Q&A
Inspection expectations, AI validation, suppliers and
cloud services
Not sure about something we covered, or thinking about how this applies to your context?
View other our other resources and company news
Article Effective QMS Management Post-Go-Live: Strategies for Governance, Releases, and Continuous Improvement
After QMS go live, compliance and performance depend on strong governance, structured release management and continuous improvement. Learn how to sustain control, adoption and long ...
Read More
Case Study GMP Consultancy for a New Manufacturing Plant
With only a small team and a highly automated process, this biotech company needed to achieve EU GMP compliance fast. This case study shows how ...
Read More
Article Why Quality Can No Longer Live in Silos
Discover why siloed quality management is no longer sustainable in life sciences. Learn how integrating audits, advisory services and digital quality systems supports continuous GxP ...
Read More
Article Why Most QMS Implementations Fail to Deliver Long-Term Value
Implementing a QMS is more than deploying software. Learn why most QMS implementations fall short, and what successful life sciences teams do differently to achieve ...
Read More
Case Study Driving Global QMS Harmonisation for a Pharmaceutical Company
This case study outlines how Rephine helped a global pharmaceutical group implement and validate a harmonised Quality Management System across more than seventy sites. It ...
Read More
Guide How to Structure MDR Technical Documentation (Annex II & III). A Practical Compliance Guide
This white paper provides a practical guide to structuring MDR Technical Documentation under Annex II and Annex III. It explains how to organise evidence, maintain ...
Read More
Blog IT Quality Assurance in Regulated Life Sciences: Key Insights
IT Quality Assurance is pivotal in regulated life sciences. From CSV and data integrity to change control and audit readiness, discover how IT QA ensures ...
Read More
General Practical compliance and inspection readiness for UK pharmaceutical quality systems
Explore how UK pharmaceutical and biotech organisations can stay prepared for MHRA, EMA and FDA inspections. This session provides expert guidance on inspection trends, compliance ...
Read More
Case Study Supporting Verification and Validation of a Medical Device Software (MDSW)
Discover how a medical device start‑up successfully verified and validated its new Medical Device Software in line with MDR requirements. With Rephine’s structured approach to ...
Read More
